Posted by Michael Wonder on 30 Jun 2022
Pfizer announces submission of new drug application to the U.S. FDA for Paxlovid
30 June 2022 - Final results from EPIC-HR study showed an 86% reduction in relative risk of hospitalisations or death from any cause; no deaths were observed in patients treated with Paxlovid (nirmatrelvir tablets and ritonavir tablets) through week 24, compared to 15 deaths observed with placebo.
Pfizer today announced the submission of a new drug application to the U.S. FDA for approval of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for patients who are at high risk for progression to severe illness from COVID-19.
